Melane Sampson, Author at BioTuesdays

Developments

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

Neurogene (NASDAQ:NGNE) has announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) annual meeting this week describing a monitoring and treatment algorithm intended to reverse the rare...

May 16, 2025

Developments

CAMP4 presents translational data from SYNGAP1-related disorders program at ASGCT annual meeting

CAMP4 Therapeutics (NASDAQ:CAMP) has announced that three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs, and shared favorable safety and pharmacokinetics data from the...

May 16, 2025

Developments

Ekso Bionics accepted into NVIDIA Connect program

Ekso Bionics Holdings (NASDAQ:EKSO) has announced its acceptance into the NVIDIA Connect program, enabling access to valuable tools and resources to support a new strategic initiative to build a proprietary foundation...

May 15, 2025

Developments

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

In a May 13, 2025 post on X, Chamath Palihapitiya, renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, provided the latest updates on Perimeter Medical Imaging AI (TSXV:PINK;...

May 14, 2025

Developments

Radiology Today spotlights Perimeter’s next-gen, AI-enabled B-Series OCT for interoperative cancer margin assessment during breast-conserving surgeries

The May issue of Radiology Today magazine features an interview with Andrew Berkeley, co-founder and chief innovation officer of Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF), and highlights both the...

May 13, 2025

Developments

Zynex submits FDA application for NiCO device

Zynex (NASDAQ:ZYXI) announced it has submitted a 510(k) application to the FDA for its NiCO Noninvasive CO-Oximeter device. The company stated that the submission marks a historic milestone in the evolution of pulse...

May 12, 2025

Developments

IPA reports new results validating in silico epitope mapping application

ImmunoPrecise Antibodies (IPA) (NASDAQ:IPA) announced new benchmarking results validating the accuracy and utility of its in silico epitope mapping application—part of the LENSai platform, which delivers x-ray-level...

May 12, 2025

Developments

FDA accepts Omeros’ BLA resubmission for narsoplimab in TA-TMA

Omeros Corporation (NASDAQ:OMER) announced that the FDA will review its resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated...

May 6, 2025

Developments

WHO approves Moleculin’s name for next-gen anthracycline

Moleculin Biotech (NASDAQ:MBRX) announced that the International Nonproprietary Names (INN) expert committee of the World Health Organization (WHO) has approved “naxtarubicin” as the non-proprietary name of its next...

May 6, 2025

Feature

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Terns Pharmaceuticals (NASDAQ:TERN) is developing a portfolio of novel, oral small-molecule product candidates based on clinically validated mechanisms of action to address serious diseases including oncology and...

May 6, 2025

Author - Melane Sampson

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

CAMP4 presents translational data from SYNGAP1-related disorders program at ASGCT annual meeting

Ekso Bionics accepted into NVIDIA Connect program

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

Radiology Today spotlights Perimeter’s next-gen, AI-enabled B-Series OCT for interoperative cancer margin assessment during breast-conserving surgeries

Zynex submits FDA application for NiCO device

IPA reports new results validating in silico epitope mapping application

FDA accepts Omeros’ BLA resubmission for narsoplimab in TA-TMA

WHO approves Moleculin’s name for next-gen anthracycline

Terns shaping the future of human health with potential best-in-class therapies for serious diseases

Subscribe